HUTCHMED Secures New AIM Block Admission for 2026 Share Option Scheme

TipRanksJun 5 16:32

CITIC Securities: Pharmaceuticals and Biologics Experience Concurrent Growth and Adjustment; Watch for Sector Bottoming and Recovery Inflection Point

The pharmaceutical distribution sector is demonstrating steady and improving revenue performance, with the effects of accounts receivable policies gradually materializing. Large central state-owned enterprises and entities showing expectations of operational improvement remain attractive investment targets.

Zhitong FinanceJun 1 10:40

Bank of America Securities Sticks to Their Buy Rating for HUTCHMED (HCM)

TipRanksJun 1 09:19 · Ratings

Morgan Stanley Reaffirms Their Hold Rating on HUTCHMED (China) (HCM)

TipRanksMay 30 08:33 · Ratings

Major Broker: Morgan Stanley's Investment Ratings and Target Prices for Chinese Biotech Stocks (Table)

Morgan Stanley published a research report listing the investment ratings and target prices for Chinese biotech stocks as follows: Stock | Investment Rating | Target Price (HKD) Confo Therapeutics-B (02162.HK) | Overweight | HK$93.5 → HK$97 Innovent Bio (01801.HK) | Overweight | HK$130 → HK$135 LegoChem Biosciences-B (09887.HK) | Equal-weight | HK$59 → HK$62 HUTCHMED (00013.HK) | Underweight → Equal-weight | HK$21.4 → HK$21.3

AASTOCKSMay 29 15:11

Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6

Futu NewsMay 29 04:31 · Ratings